CALLY Index: Prognostic Biomarker for Surgically Treated NSCLC Patients

680 patient records from a retrospective study evaluating the prognostic value of the C-reactive protein-albumin-lymphocyte (CALLY) index in non-small cell lung cancer. The dataset likely contains clinical characteristics, biomarker values, and survival outcomes for patients who underwent curative-intent surgery. It was authored by Kun Woo Kim and last updated in March 2026.

Use Cases

• Validate the prognostic performance of the CALLY index based on overall survival analysis.
• Compare biomarker discriminative power using time-dependent receiver operating characteristic analysis.
• Perform risk stratification for postoperative surveillance based on the CALLY index cut-off value.
• Investigate the consistency of biomarker associations across pathological stage and smoking status.

Strengths

• 680 patient records provide a substantial cohort for analysis.
• The CALLY index demonstrated the highest AUC (0.675) among evaluated markers.
• Propensity score matching generated 416 matched pairs with balanced characteristics.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• The dataset is limited to a single study's retrospective cohort.

Provenance

Source

figshare

Collection Method

Retrospective analysis of patients who underwent curative-intent surgery for NSCLC.

Freshness

Last updated 2026-03-19 05:17:23; freshness should be verified.